Killick Capital

Killick Capital Inc. is a private equity firm founded in 2004 and headquartered in St. John's, Newfoundland and Labrador. The firm specializes in acquisitions, restructurings, and investments in undervalued companies, with a particular focus on the aerospace sector and private businesses located in Atlantic Canada. Killick Capital aims to partner with its portfolio companies, often taking board membership to enhance collaboration and drive growth. The firm provides capital for expansion and acquisition financing, positioning itself as a key player in supporting the development of businesses within its targeted regions.

Joe McKenna

Partner and Vice President, Investments

Tom Williams

Vice President, Investments and Partner

Past deals in Newfoundland

Landwash Brewery

Venture Round in 2022
Landwash Brewery is a craft brewery that specializes in producing a variety of beers, including blonde ale, New England IPA, and sour ale infused with Newfoundland sea salt. The brewery features a taproom and a retail store, providing a space for friends and family to enjoy drinks and food in a relaxed environment. By offering a diverse selection of craft beers, Landwash Brewery aims to create an inviting atmosphere for customers looking to unwind and socialize.

Sequence Bio

Seed Round in 2016
Sequence Bio is a biotechnology company focused on enhancing drug discovery and development by leveraging the genetic diversity found in isolated populations, particularly in Newfoundland. The company aims to improve the treatment of complex and inherited diseases through its genome therapy platform, which involves collecting DNA and health information from these unique populations. By understanding the genetic factors that contribute to disease, Sequence Bio seeks to identify better drug targets and create more effective medicines, ultimately addressing the high failure rate of drug candidates and expediting the delivery of much-needed therapies to patients.

Sequence Bio

Pre Seed Round in 2015
Sequence Bio is a biotechnology company focused on enhancing drug discovery and development by leveraging the genetic diversity found in isolated populations, particularly in Newfoundland. The company aims to improve the treatment of complex and inherited diseases through its genome therapy platform, which involves collecting DNA and health information from these unique populations. By understanding the genetic factors that contribute to disease, Sequence Bio seeks to identify better drug targets and create more effective medicines, ultimately addressing the high failure rate of drug candidates and expediting the delivery of much-needed therapies to patients.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.